215 related articles for article (PubMed ID: 28630044)
1. Single-molecule Förster resonance energy transfer (FRET) analysis discloses the dynamics of the DNA-topoisomerase II (Top2) interaction in the presence of TOP2-targeting agents.
Huang WC; Lee CY; Hsieh TS
J Biol Chem; 2017 Jul; 292(30):12589-12598. PubMed ID: 28630044
[TBL] [Abstract][Full Text] [Related]
2. Single-molecule measurements of the opening and closing of the DNA gate by eukaryotic topoisomerase II.
Smiley RD; Collins TR; Hammes GG; Hsieh TS
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):4840-5. PubMed ID: 17360343
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the eukaryotic topoisomerase II DNA gate: a single-molecule FRET and structural perspective.
Collins TR; Hammes GG; Hsieh TS
Nucleic Acids Res; 2009 Feb; 37(3):712-20. PubMed ID: 19155278
[TBL] [Abstract][Full Text] [Related]
4. Atp-bound topoisomerase ii as a target for antitumor drugs.
Wang H; Mao Y; Zhou N; Hu T; Hsieh TS; Liu LF
J Biol Chem; 2001 May; 276(19):15990-5. PubMed ID: 11278845
[TBL] [Abstract][Full Text] [Related]
5. Monitoring the topoisomerase II DNA gate conformational change with fluorescence resonance energy transfer.
Collins TR; Hsieh TS
Methods Mol Biol; 2009; 582():59-70. PubMed ID: 19763942
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate.
Chen SF; Huang NL; Lin JH; Wu CC; Wang YR; Yu YJ; Gilson MK; Chan NL
Nat Commun; 2018 Aug; 9(1):3085. PubMed ID: 30082834
[TBL] [Abstract][Full Text] [Related]
7. Bioflavonoids cause DNA double-strand breaks and chromosomal translocations through topoisomerase II-dependent and -independent mechanisms.
Goodenow D; Emmanuel F; Berman C; Sahyouni M; Richardson C
Mutat Res Genet Toxicol Environ Mutagen; 2020 Jan; 849():503144. PubMed ID: 32087851
[TBL] [Abstract][Full Text] [Related]
8. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
9. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of topoisomerase 2 DNA-protein crosslink resolution.
Riccio AA; Schellenberg MJ; Williams RS
Cell Mol Life Sci; 2020 Jan; 77(1):81-91. PubMed ID: 31728578
[TBL] [Abstract][Full Text] [Related]
11. Targeting DNA topoisomerase II in cancer chemotherapy.
Nitiss JL
Nat Rev Cancer; 2009 May; 9(5):338-50. PubMed ID: 19377506
[TBL] [Abstract][Full Text] [Related]
12. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
13. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.
Wu CC; Li YC; Wang YR; Li TK; Chan NL
Nucleic Acids Res; 2013 Dec; 41(22):10630-40. PubMed ID: 24038465
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced conformational population shifts in topoisomerase-DNA ternary complexes.
Huang NL; Lin JH
Molecules; 2014 Jun; 19(6):7415-28. PubMed ID: 24905608
[TBL] [Abstract][Full Text] [Related]
15. The C-terminal 20 Amino Acids of Drosophila Topoisomerase 2 Are Required for Binding to a BRCA1 C Terminus (BRCT) Domain-containing Protein, Mus101, and Fidelity of DNA Segregation.
Chen YT; Wu J; Modrich P; Hsieh TS
J Biol Chem; 2016 Jun; 291(25):13216-28. PubMed ID: 27129233
[TBL] [Abstract][Full Text] [Related]
16. Incomplete reversion of double stranded DNA cleavage mediated by Drosophila topoisomerase II: formation of single stranded DNA cleavage complex in the presence of an anti-tumor drug VM26.
Lee MP; Hsieh T
Nucleic Acids Res; 1992 Oct; 20(19):5027-33. PubMed ID: 1329036
[TBL] [Abstract][Full Text] [Related]
17. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
18. Locking the DNA gate of DNA gyrase: investigating the effects on DNA cleavage and ATP hydrolysis.
Williams NL; Maxwell A
Biochemistry; 1999 Oct; 38(43):14157-64. PubMed ID: 10571989
[TBL] [Abstract][Full Text] [Related]
19. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.
Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK
Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
